The license extension for Novo Nordisk’s Victoza® means the drug is now available to almost one million people in the UK who are affected by type 2 diabetes and moderate renal impairment.

The decision by the European Commission (EC) means clinicians can treat patients with one daily injection. providing an effective treatment in an area where few treatments are available due to additional complications associated with chronic kidney disease

Currently kidney disease accounts for 11 percentof the cost of managing complications of type 2 diabetes to the National Health Service.